Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications
Eleni T. Tzavara(Inserm), Bruno Giros(Centre National de la Recherche Scientifique), Larissa Moutsimilli(Inserm), George G. Nomikos(Amgen (United Kingdom)), Tiziana Bisogno(University of Aberdeen), Lee A. Phebus(Eli Lilly (United States)), Dominic L. Li(Eli Lilly (United States)), Vincenzo Di Marzo(Natural Sciences and Engineering Research Council of Canada)
Cited by 140
Related Papers
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
|Nature|1990|2.6k
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
|Nature|1996|2.5k
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism
|Nature Genetics|2003|1.8k
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963